A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors

Overview of attention for article published in Frontiers in oncology, January 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 76 X posts from 43 X users, with an upper bound of 240,771 followers.

@HKennecke @ErikMittraMD @AB_NucMed @NovartisCancer @RebeccaKSWong @LACNETS Great article on an important topic @HKennecke. Related, we also did a piece ✍🏽 4 years ago @FrontOncology on the care process model once 177-Lu 1st became approved in 🇺🇸. A lot t

RT @pashtoonkasi: At @FLASCO_ORG @ClevelandClinic today presenting our care process model for #PRRT. THERA-(py)➕(diag)-NOSTICS ➡️THERANOSTI…

RT @pashtoonkasi: At @FLASCO_ORG @ClevelandClinic today presenting our care process model for #PRRT. THERA-(py)➕(diag)-NOSTICS ➡️THERANOSTI…

RT @pashtoonkasi: At @FLASCO_ORG @ClevelandClinic today presenting our care process model for #PRRT. THERA-(py)➕(diag)-NOSTICS ➡️THERANOSTI…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 72 additional X posts.